Skip to main content
. 2002 Sep;46(9):2727–2734. doi: 10.1128/AAC.46.9.2727-2734.2002

TABLE 2.

MICs of macrolides and related antibiotics for ribosomal mutants of S. pneumoniae selected in vitro

Resistance phenotype Gene (product) Alteration(s) MIC (μg/ml) ofa:
Reference(s)
AZM CLR ERY SPI JOS TEL SGB PRI CLI
MLSB rrl (23S rRNA domain V) A2058G or A2058U >32->200 16-100 >32->100 6.25 ND 0.06-1 12.5 0.5 0.2-4 5, 40
ML rrl (23S rRNA domain V) A2059G >32 2 8 ND ND 0.015 ND 0.25 2 5, 40
ML (low level) rrl (23S rRNA domain V) C2610U 0.125 0.03 0.06 ND ND 0.008 ND 0.5 0.5 5
MSB rrl (23S rRNA domain V) C2611A, C2611G, or C2611U 0.5-12.5 0.06-100 0.06->100 0.78-1.56 ND 0.01-0.39 50->100 0.5 0.2-2 5, 40
MKLSB rrl (23S rRNA domain II) A752 deletion >32 >32 >32 ND ND 4 ND 1 1 5
MSB rplD (L4 protein) G69C and 67QSQKb 0.39-1.56 0.05-0.2 0.05-0.2 ND 0.78-1.56 0.006-0.1 3.12 ND 0.05-0.2 40
MS rplV (L22 protein) G95D, P99Q, A93E, P91S, and G83E 0.06-1 0.125-1 0.25-1 ND ND 0.06-0.25 ND 1-2 0.03-0.12 5
a

AZM, azithromycin; CLR, clarithromycin; ERY, erythromycin; SPI, spiramycin; JOS, josamycin, TEL, telithromycin; SGB, streptogramin B; PRI, pristinamycin IA; CLI, clindamycin. ND, not determined.

b

The alteration is underlined.

HHS Vulnerability Disclosure